Test and Establishment of Using Monocytes and Monocyte-Derived Macrophages as a Novel Therapeutic Delivery System to the Brain
Year: 2016
Type: dissertation
Abstract: 2.7 References ………………………………….………………………………………….50 Chapter 3. Physiological function and inflamed-brain migration of mouse monocyte-derived macrophages following cellular uptake of superparamagnetic iron oxide nanoparticles -implication of macrophagebased drug delivery into the central nervous system …………………………………… 68 x LIST OF FIGURES 2.1 Condition optimization for exogenous MDM delivery into acutely inflamed brain tissue ...…………………………………………………………………….. 55 2.2 Migration efficiency of IV transferred cMDM to acutely inflamed brain tissue is linked to monocyte-to-macrophage differentiation ...…………….56 2.3 EnMO characterizations ...……………....……………....……………....……………....... 58 2.4 EnMO migrate into inflamed brain region with significant higher efficiency compared to cMDM ...……………....……………....………………………... 59 2.5 IV transferred monocytes ingression in brain ...……………....………………….60 2.6 Expression analysis of selected cytokine genes in inflamed brain region ...……………....……………....……………....……………....……………....…………... 61 2.7 Enhanced monocytes entry into the inflamed brain ...………………………… 62 2.8 Recruited monocytes matured into cells with two distinguish morphologies in the brain ...……………....……………....……………....……………... 63 2.9 Recruited monocytes differentiated into IBA-1 positive cells with microglia morphology in the brain ...……………....……………....………………….64 2.10 Distribution of IV infused monocytes and brain resident astrocytes in the inflamed brain ...……………....……………....……………....……………....………… 65 2.11 Monocyte-mediated delivery of SHP30 and GFP gene to the brain ……… 66 3.1 Quantification of SPIONs uptake in MDM ...……………....……………....………... 98 3.2 Cell viability assays of MDM treated with different SPION at indicated concentrations ...……………....……………....……………....……………....……………… 99 3.3 Assessment of selected cytokine transcription level of MDM post overnight incubation with SHP30 at indicated concentrations …………… 100 3.4 SHP30-induced monocyte to macrophage differentiation ...………………... 101 3.5 Control and SHP30-carraige MDM are recruited to the inflamed region in the brain ...……………....……………....……………....……………....…………………… 102 3.6 MDM carriage of SHP30 at 48 hours following particle uptake …………… 103 3.7 Alternation in SHP30-laden MDM in vivo disease-homing efficiency …... 104 xi 4.1 Schematic map of the lentiviral transfer plasmid pD101-sTNFR:Fc-IRES-eGFP ...……………....……………....……………....……………....…………………….. 4.2 LV-mediated gene transfer into mouse primary monocytes ...…………….. 4.3 Evaluation on carrier-monocytes brain migration and transgene expression ...……………....……………....……………....……………....…………………….4.4 Comparison on the in vivo tissue distribution of Ctl-MO and TD-MO …... 4.5 TD-MO mediated sTNFR:Fc expression in end organs ...……………………… 4.6 LV-mediated gene transfer into mouse primary cMDM ...…………………….4.7 in vivo tissue distribution of Ctl-MO and Ctl-cMDM following IV infusion ...……………....……………....……………....……………....……………....………... 5.1 LV-mediated sTNFR gene transfer into primary mouse monocytederived macropahges ...……………....……………....……………....…………………….5.2 Migration of ICV-infused Ctl-MDM from lateral ventricle to the inflamed parenchyma located on the opposite hemisphere ...……………… 5.3 Altered migratory pattern of ICV-infused sTNFR/GFP-MDM ...…………….5.4 Migration of ICV-infused GFP-MDM from lateral ventricle to the inflamed parenchyma ...……………....……………....……………....……………....…… 5.5 Extrasavated sTNFR/GFP-MDM displayed branched morphology and expressed IBA-1 marker ...……………....……………....
Author: Hsin-I Tong
Institution: University of Hawaiʻi at Mānoa
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Keywords: monocyte-derived macrophages, monocytes, brain drug delivery, superparamagnetic iron oxide nanoparticles, neuroinflammation, monocyte-to-macrophage differentiation, gene delivery to the brain, microglia, astrocytes, nanoparticle toxicity, blood-brain barrier, cytokine expression, neuroprotection, neurodegeneration
Open Access status: green
OpenAlex ID: W2781808725
